No connection

Search Results

HYPR vs IMDX

HYPR
Hyperfine, Inc.
NEUTRAL
Price
$1.21
Market Cap
$119.2M
Sector
Healthcare
AI Confidence
85%
IMDX
Insight Molecular Diagnostics Inc.
BEARISH
Price
$3.17
Market Cap
$102.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HYPR
--
IMDX
--
Forward P/E
HYPR
-3.67
IMDX
-3.77
P/B Ratio
HYPR
2.87
IMDX
-2.89
P/S Ratio
HYPR
8.79
IMDX
25.15
EV/EBITDA
HYPR
-2.33
IMDX
-3.32

Profitability

Gross Margin
HYPR
49.79%
IMDX
56.84%
Operating Margin
HYPR
-144.87%
IMDX
-873.57%
Profit Margin
HYPR
-262.29%
IMDX
0.0%
ROE
HYPR
-79.01%
IMDX
--
ROA
HYPR
-40.61%
IMDX
-62.66%

Growth

Revenue Growth
HYPR
128.0%
IMDX
-23.4%
Earnings Growth
HYPR
--
IMDX
--

Financial Health

Debt/Equity
HYPR
0.01
IMDX
--
Current Ratio
HYPR
4.34
IMDX
1.27
Quick Ratio
HYPR
3.56
IMDX
1.05

Dividends

Dividend Yield
HYPR
--
IMDX
--
Payout Ratio
HYPR
0.0%
IMDX
0.0%

AI Verdict

HYPR NEUTRAL

HYPR presents a high-risk, high-reward profile characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation benchmarks due to negative earnings. The company is experiencing explosive revenue growth (128% YoY) and maintains a strong liquidity position with a Current Ratio of 4.34 and negligible debt. However, these strengths are offset by severe profit margins (-262.29%) and a bearish insider sentiment. The stock is currently a speculative growth play where the market is pricing in future scalability rather than current fundamentals.

Strengths
Explosive revenue growth of 128% YoY
Strong liquidity with a Current Ratio of 4.34
Very low leverage (Debt/Equity of 0.01)
Risks
Severe negative profit margins (-262.29%)
Bearish insider activity with consistent selling by C-suite executives
High valuation relative to sales (P/S of 8.79) for a non-profitable firm
IMDX BEARISH

IMDX exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book: -2.89) and a catastrophic operating margin of -873.57%, suggesting an unsustainable business model. Revenue is contracting rapidly (-23.4% YoY), and the earnings track record is abysmal with 0 beats in the last four quarters. Despite optimistic analyst price targets, the deterministic data points toward a high risk of insolvency or significant further dilution.

Strengths
Positive gross margin of 56.84%
Current ratio of 1.27 provides a minimal short-term liquidity buffer
Positive analyst sentiment with a target price of $8.33
Risks
Negative shareholder equity (Price/Book -2.89)
Severe revenue contraction (-23.4% YoY and Q/Q)
Extreme operating losses (-873.57% operating margin)

Compare Another Pair

HYPR vs IMDX: Head-to-Head Comparison

This page compares Hyperfine, Inc. (HYPR) and Insight Molecular Diagnostics Inc. (IMDX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile